ALLODX
Research Frontiers
Industry Frontier | ASN 2026 Complement Research Update
Tissue targeting · mechanism matching · activity assessment—from 68 core complement-related abstracts, what kidney disease research is asking.
Read more ↗
Nature Study Maps Immune Responses to Pig Kidney Xenotransplantation
Facing the global organ shortage crisis, gene-edited pig organs are seen as a beacon of hope for saving lives. However, even after gene editing, the strong immune rejection after cross-species…
Read more ↗
Prospective case: follow-up of a preoperative Nephrin antibody-positive patient after desensitization treatment
Recently, the magazine "Kidney International" reported a case of a pediatric patient with primary focal segmental glomerulosclerosis (pFSGS) who cleared Nephrin antibodies before kidney…
Read more ↗
Frontiers of Xenotransplantation | NEJM Case Report: Gene-edited pig kidney xenotransplantation brings new hope to patients with end-stage renal disease
Recently, the New England Journal of Medicine (NEJM) published a xenotransplantation case report from Massachusetts General Hospital in the United States. Researchers at the hospital successfully…
Read more ↗
Industry Frontier | Pig kidney-derived cell-free DNA (xd-cfDNA) enables early warning of xenogeneic kidney transplant rejection
Recently, a study published in the journal Xenotransplantation provides a new and important direction for postoperative monitoring of kidney xenotransplantation. The study was completed by a team of…
Read more ↗
2022ATC in-depth interpretation (3): Factors affecting dd-cfDNA detection values
As dd-cfDNA enters the clinical application stage of transplantation, it is necessary to correctly interpret the clinical significance of the detection values. On the one hand, we are required to…
Read more ↗
2022ATC in-depth interpretation (2): In-depth correlation analysis between dd-cfDNA detection and Banff pathological indicators
In studies pairing donor-derived cell-free DNA (dd-cfDNA) detection with biopsy pathology, dd-cfDNA has been shown to be diagnostic of rejection. With the deepening of research, clinical trials have…
Read more ↗
ATC2022 in-depth interpretation (1): dd-cfDNA clinical usage scenarios and usage experience summary
As the clinical application of dd-cfDNA in kidney transplantation continues to expand, transplant centers around the world continue to deepen their understanding of the synergistic value between…
Read more ↗
ATC2022 Review: In-depth interpretation of global progress of dd-cfDNA
From June 4 to 8, the five-day American Transplantation Conference (ATC) was held in Boston, USA. The conference had a forward-looking theme of "The Science of Tomorrow Starts Today" and covered many…
Read more ↗
Industry Frontier | Am J Transplant magazine research results reveal the similarities and differences between DSA-positive and DSA-negative mABMR at the clinical manifestations, pathological biopsy and molecular level
On May 16, the American Journal of Organ Transplantation (Am J Transplant) published the results of a study online. The study compared the clinical manifestations, pathological biopsy and…
Read more ↗
Industry Frontier | Researchers transform type A blood donor lungs into universal blood type donor lungs through enzymatic treatment
Recently, Canadian researchers say they have found a way to help people who would otherwise languish on the organ transplant list. In their new study, they detail converting lungs from people with…
Read more ↗
ATC 2021: dd-cfDNA for Subclinical Screening (Part 3)
The clinical manifestations of subclinical rejection are not obvious, and procedural biopsy is currently the main method to detect subclinical rejection. However, its application is limited due to…
Read more ↗ATC 2021: dd-cfDNA, Risk Stratification and Prognosis (Part 2)
At present, research on donor-derived cell-free DNA (dd-cfDNA) mainly focuses on the diagnosis of rejection, but there are few reports on its use for prognostic factor analysis and risk…
Read more ↗ATC 2021: Perspectives on Donor-derived Cell-free DNA (Part 1)
At this year's American Transplantation Annual Conference (ATC 2021), donor-derived cfDNA (dd-cfDNA), an emerging biomarker in the field of transplantation liquid biopsy, continues to become a…
Read more ↗
Transpl Infect Dis: COVID-19 survivors may be safe organ donors
The new coronavirus has been raging around the world for 18 months since it was first reported. While the virus poses a huge threat to human life, it has also profoundly affected the global…
Read more ↗
"Nature Reviews Nephrology" published a review: dd-cfDNA can be used to detect kidney transplant damage
Recently, the international authoritative medical journal Nature Reviews Nephrology published a review focusing on the transplant liquid biopsy biomarker—dd-cfDNA. It proposes that clinical…
Read more ↗
New York State approves Eurofins Viracor new kidney transplant rejection biomarker test
Eurofins Viracor and Transplant Genomics stated that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the company's Viracor TRAC donor-derived…
Read more ↗
Industry Frontier | The impact of urinary tract infection on dd-cfDNA detection values
Urinary tract infection is one of the most common infections after kidney transplantation, with an incidence rate of 20%-80% after transplantation. Studies have suggested that urinary tract infection…
Read more ↗
Industry News | NephroSant launches urine sample-based kidney transplant rejection diagnostic product
About 20% of kidney transplant patients require retransplantation every year, and acute rejection is an important factor affecting the long-term survival of the transplanted kidney. Early and…
Read more ↗
Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (3)
In the last two issues, the editor introduced to you the new progress of donor-derived cell-free DNA (dd-cfDNA) in transplantation liquid biopsy at the ATC conference. In this issue, the editor will…
Read more ↗Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (2)
In the last issue, the editor introduced to you the new progress of transplant liquid biopsy (donor-derived cell-free DNA, dd-cfDNA) at the ATC meeting. In this issue, the editor will continue to…
Read more ↗
Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (1)
Due to the COVID-19 pandemic in 2020, the American Transplant Congress (ATC), originally scheduled for May 30 to June 3 in Philadelphia, was held online for the first time, presenting cutting-edge…
Read more ↗
Industry News | CareDx partners with Weill Cornell Medicine to use urine samples to diagnose acute rejection
Recently, CareDx, a molecular diagnostics company focusing on organ transplantation, announced a strategic alliance with Weill Cornell Medicine to use UroMap detection technology to diagnose T…
Read more ↗
Transplant Liquid Biopsy | Molecular Stethoscope for Organ Health Monitoring
Organ transplantation is known as one of the three major application fields in the era of liquid biopsy. It is the next emerging direction of liquid biopsy application after non-invasive prenatal…
Read more ↗
CareDx launches cell-free DNA-based non-invasive detection product for kidney transplant rejection
CareDx (CNDA), a Nasdaq-listed company based in California, USA, recently released AlloSure, a non-invasive detection product for rejection after kidney transplantation.
Read more ↗
To protect the health of transplanted organs, a cutting-edge company raised tens of millions of dollars in Series A financing!
Emerging name: TAI Diagnostics Company location: Wauwatosa, Wisconsin, USA
Read more ↗
He Xiaoshun's team at Sun Yat-Sen First Hospital successfully performed the world's first "no ischemia" kidney transplant
Recently, Professor He Xiaoshun’s team at our hospital’s Organ Transplantation Center successfully performed the world’s first “ischemia-free” kidney transplantation. This is the first time that the…
Read more ↗No matching content. Try another keyword or view all categories.